Stem cells ramping up.., page-69

The J P Morgan healthcare conference may be over bit that doesn't mean the deal making is over , often deals that took shape at the meeting materialise later in the year ,and some recent buzz puts Pfizer and Biogen and the centre of potential deals ...Pfizer is reportedly eyeing a buyout of cardiovascular player Amarin ..Meanwhile Biogen could be another player if JPM executives are any indications , " The big Biotech would love to get it's hands on something a bit larger with multiple phase 3 assets " management said, as quoted by Mizuho analyst Salim Syed who noted the company has $ 13 bill.worth of finance capacity ..That kind-of deal would invoke a change of business development strategy for Biogen which has traditionally done early stage deals ..........


The long awaited M&A boom will hit Biopharma in 2019 despite the constant worries Prognosticators predict ....As Col would state " just saying "